Latest News - Page 2 of 46 - Oklahoma Society of Clinical Oncology

OSCO and ASCO Supported Co-Pay Accumulator Ban Bill Signed into Law

On April 19, Oklahoma Governor Kevin Stitt (R) signed co-pay accumulator ban bill HB 2678 into law. This measure requires Pharmacy Benefit Managers (PBMs) to include any amount paid by an enrollee, or on behalf of an enrollee, when calculating the enrollee’s out of pocket maximum, copay, coinsurance, deductible, or cost sharing requirement. The Oklahoma […]

Read More

Natera announces allocation of $1,000,000 to Signatera Research Fund for initiatives that focus on using Signatera to develop or refine specific and defined medical knowledge.

Signatera Research Fund Natera supports independent research and education initiatives from the global healthcare community that align with Natera’s medical and scientific strategy for improving patient outcomes in areas of unmet medical need. This year, Natera has allocated $1,000,000 for research initiatives that are focused on using Signatera to develop or refine specific and defined […]

Read More

FDA approves KEYTRUDA® (pembrolizumab) for additional treatment.

Merck has announced that the FDA has approved KEYTRUDA® (pembrolizumab) for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. PD-L1 diagnostic testing is […]

Read More

Oncopeptides offers new FDA Approved Treatment Option for Some Patients with Triple-Class Refractory Multiple Myeloma

Oncopeptides will host a seminar to explore a new therapy for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Join OncLive® and Oncopeptides, along with experts […]

Read More

USDA Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines […]

Read More

FDA approves Bristol Myers Squibb’s Onureg® (azacitidine tablets) for Continued Treatment of Acute Myeloid Leukemia

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg® (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or CR with incomplete blood count recovery (CRi) following intensive induction chemotherapy and who are not able […]

Read More

Bristol Myers Squibb’s Breyanzi approved by FDA

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not […]

Read More

FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class Refractory Multiple Myeloma

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO),  a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple […]

Read More

PFIZER’S XALKORI® (CRIZOTINIB) APPROVED BY FDA FOR ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IN CHILDREN AND YOUNG ADULTS

Pfizer Inc. (NYSE:PFE) recently announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The safety […]

Read More

U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

Bristol Myers Squibb (NYSE: BMY) today announced that OPDIVO®(nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX® (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).1 The approval is […]

Read More